1-aminoindan

1-Aminoindan ,with CAS No. 34698-41-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 1-Aminoindan provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

1-Aminoindane hydrochloride ,with CAS No. 70146-15-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 1-Aminoindane hydrochloride provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

N-Boc-D,L-1-aminoindane-1-carboxylic acid ,with CAS No. 214139-26-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. N-Boc-D,L-1-aminoindane-1-carboxylic acid provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

(1S,2R)-1-Aminoindan-2-ol is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

Rasagiline-13C3 (mesylate) is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline (mesylate) (T6962) is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo (ED50= 0.1 mg/kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease.